$AAGH
America Great Health Stock $aagh

$aagh Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-K Financial Statement

#000118518523001064 Filed on October 13, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2023
Revenue	$13.81K	$74.69K	$204.3K
YoY Change	-73.41%	-28.63%	95.23%
Cost Of Revenue	$177.00	$30.00	$35.72K
YoY Change	-99.36%	-100.0%	-97.75%
Gross Profit	$13.63K	$74.66K	$168.6K
YoY Change	-44.22%	-105.03%	-111.36%
Gross Profit Margin	98.72%	99.96%	82.52%
Selling, General & Admin	$88.57K	$232.2K	$661.2K
YoY Change	-41.98%	-92.85%	-79.66%
% of Gross Profit	649.76%	311.06%	392.22%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$3.697K	$3.700K	$10.35K
YoY Change	150.47%	-37.39%	75.21%
% of Gross Profit	27.12%	4.96%	6.14%
Operating Expenses	$88.57K	$232.2K	$661.2K
YoY Change	-41.98%	-92.85%	-79.66%
Operating Profit	-$74.94K	-$157.6K	-$492.6K
YoY Change	-41.56%	-96.67%	-89.59%
Interest Expense	$82.05K	-$85.22K	$319.7K
YoY Change	27.13%	-55.36%	67.46%
% of Operating Profit
Other Income/Expense, Net	-$82.04K	-$20.00	-$284.7K
YoY Change	27.13%	-128.57%	49.18%
Pretax Income	-$157.0K	-$242.8K	-$777.3K
YoY Change	-18.56%	-95.07%	-84.22%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$157.0K	-$241.8K	-$777.3K
YoY Change	-18.56%	-95.03%	-84.22%
Net Earnings / Revenue	-1136.88%	-323.72%	-380.47%
Basic Earnings Per Share
Diluted Earnings Per Share	$0.00	$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	21.11B shares	21.09B shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q3	2023 Q2	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$54.63K	$54.15K	$54.15K
YoY Change	-26.74%	-13.55%	-13.55%
Cash & Equivalents	$54.63K	$54.15K
Short-Term Investments
Other Short-Term Assets	$16.97K	$16.96K	$16.96K
YoY Change	0.0%	0.0%	0.0%
Inventory	$108.2K	$108.4K	$108.4K
Prepaid Expenses
Receivables	$0.00	$0.00	$0.00
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$179.8K	$179.5K	$179.5K
YoY Change	-15.88%	-8.71%	-8.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$54.00K	$57.69K	$99.61K
YoY Change	143.86%	144.27%	-15.23%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$8.218K	$8.218K	$11.84K
YoY Change	-75.86%	-40.6%	-14.45%
Total Long-Term Assets	$97.15K	$119.7K	$119.7K
YoY Change	-30.85%	-14.26%	-14.25%
TOTAL ASSETS
Total Short-Term Assets	$179.8K	$179.5K	$179.5K
Total Long-Term Assets	$97.15K	$119.7K	$119.7K
Total Assets	$276.9K	$299.1K	$299.1K
YoY Change	-21.81%	-11.01%	-11.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.448M	$1.451M	$1.451M
YoY Change	0.96%	0.91%	0.91%
Accrued Expenses	$23.10K	$41.92K	$41.92K
YoY Change	-65.44%	-40.87%	-40.87%
Deferred Revenue
YoY Change
Short-Term Debt	$690.6K	$705.2K	$705.2K
YoY Change	350.35%	283.41%	283.42%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.150M	$3.092M	$3.092M
YoY Change	13.25%	12.13%	12.13%
LONG-TERM LIABILITIES
Long-Term Debt	$1.123M	$1.123M	$1.123M
YoY Change	-0.79%	8.82%	8.82%
Other Long-Term Liabilities	$684.0K	$609.9K	$609.9K
YoY Change	44.48%	49.83%	49.83%
Total Long-Term Liabilities	$1.123M	$1.733M	$1.733M
YoY Change	-0.79%	20.42%	20.42%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.150M	$3.092M	$3.092M
Total Long-Term Liabilities	$1.123M	$1.733M	$1.733M
Total Liabilities	$4.957M	$4.825M	$4.750M
YoY Change	12.99%	14.97%	14.8%
SHAREHOLDERS EQUITY
Retained Earnings	-$9.339M	-$9.183M
YoY Change	8.55%	9.04%
Common Stock	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.605M	-$4.451M	-$4.451M
YoY Change
Total Liabilities & Shareholders Equity	$276.9K	$299.1K	$299.1K
YoY Change	-21.81%	-11.01%	-11.01%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2023
OPERATING ACTIVITIES
Net Income	-$157.0K	-$241.8K	-$777.3K
YoY Change	-18.56%	-95.03%	-84.22%
Depreciation, Depletion And Amortization	$3.697K	$3.700K	$10.35K
YoY Change	150.47%	-37.39%	75.21%
Cash From Operating Activities	-$120.8K	-$141.1K	-$752.9K
YoY Change	-15.66%	-12.32%	-49.12%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$44.42K
YoY Change			163.6%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00	-$44.42K
YoY Change			163.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$92.08K
YoY Change			-5.56%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$118.5K	140.7K	$789.3K
YoY Change	-23.59%	20.11%	-32.13%
NET CHANGE
Cash From Operating Activities	-$120.8K	-141.1K	-$752.9K
Cash From Investing Activities	$0.00	0.000	-$44.42K
Cash From Financing Activities	$118.5K	140.7K	$789.3K
Net Change In Cash	$476.00	-450.0	-$7.994K
YoY Change	-96.01%	-98.97%	-97.6%
FREE CASH FLOW
Cash From Operating Activities	-$120.8K	-$141.1K	-$752.9K
Capital Expenditures	$0.00	$0.00	$44.42K
Free Cash Flow	-$120.8K	-$141.1K	-$797.3K
YoY Change	-15.66%	-12.32%	-46.73%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	23618	usd
CY2023Q2	us-gaap	Assets Assets	299129	usd
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-27873
CY2023	dei	Entity Registrant Name EntityRegistrantName	America Great Health
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	WY
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-0178621
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	1609 W Valley Blvd Unit 338A
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Alhambra
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91803
CY2023	dei	City Area Code CityAreaCode	(888)
CY2023	dei	Local Phone Number LocalPhoneNumber	988-1333
CY2023	dei	Security12b Title Security12bTitle	None
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	21107018148	shares
CY2023	dei	Auditor Name AuditorName	Gries & Associates, LLC
CY2023	dei	Auditor Location AuditorLocation	Denver, Colorado
CY2023	dei	Auditor Firm AuditorFirmId	6778
CY2023Q2	us-gaap	Cash Cash	54150	usd
CY2022Q2	us-gaap	Cash Cash	62643	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	918	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	108351	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	116060	usd
CY2023Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	0	usd
CY2022Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	0	usd
CY2023Q2	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	16964	usd
CY2022Q2	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	16964	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	179465	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	196585	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	41918	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	93886	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8218	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8218	usd
CY2023Q2	us-gaap	Deposit Assets DepositAssets	11836	usd
CY2022Q2	us-gaap	Deposit Assets DepositAssets	13836	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	57692	usd
CY2022Q2	us-gaap	Assets Assets	336143	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1450574	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1437522	usd
CY2023Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	3970	usd
CY2022Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	102	usd
CY2023Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	705216	usd
CY2022Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	183932	usd
CY2023Q2	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	241784	usd
CY2022Q2	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	334112	usd
CY2023Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	425142	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	573859	usd
CY2023Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	223331	usd
CY2022Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	157000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	41918	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	70895	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3091935	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2757422	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	22991	usd
CY2023Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	609892	usd
CY2022Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	384073	usd
CY2023Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1123138	usd
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1032138	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1733030	usd
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1439202	usd
CY2023Q2	us-gaap	Liabilities Liabilities	4824965	usd
CY2022Q2	us-gaap	Liabilities Liabilities	4196624	usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	usd
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21107018148	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21107018148	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21090218148	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21090218148	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4732477	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4619991	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	500	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-160	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-500	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	160	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-9183110	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8421849	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-4451133	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-3801698	usd
CY2023Q2	us-gaap	Minority Interest MinorityInterest	-74703	usd
CY2022Q2	us-gaap	Minority Interest MinorityInterest	-58783	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4525836	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3860481	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	299129	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	336143	usd
CY2023	us-gaap	Revenues Revenues	204308	usd
CY2022	us-gaap	Revenues Revenues	104648	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	35720	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1588453	usd
CY2023	us-gaap	Gross Profit GrossProfit	168588	usd
CY2022	us-gaap	Gross Profit GrossProfit	-1483805	usd
CY2023	us-gaap	Selling Expense SellingExpense	3999	usd
CY2022	us-gaap	Selling Expense SellingExpense	86316	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	657233	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3163977	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	661232	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3250293	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-492644	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-4734098	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	26	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	5	usd
CY2023	us-gaap	Interest Expense InterestExpense	319705	usd
CY2022	us-gaap	Interest Expense InterestExpense	190916	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	usd
CY2023	us-gaap	Other Income OtherIncome	34983	usd
CY2022	us-gaap	Other Income OtherIncome	73	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-284696	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-190838	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-777340	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4924936	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-777340	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4924936	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-15920	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-58783	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-761420	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4866153	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-760920	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4866313	usd
CY2023	aagh	Earnings Per Share Basic And Diluted1 EarningsPerShareBasicAndDiluted1	0
CY2022	aagh	Earnings Per Share Basic And Diluted1 EarningsPerShareBasicAndDiluted1	0
CY2023	aagh	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	21093402806	shares
CY2022	aagh	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	21090049276	shares
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-467827	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	97500	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1361133	usd
CY2022	aagh	Imputed Interest ImputedInterest	11893	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	160	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	61596	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4924936	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3860481	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3860481	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	26200	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	65880	usd
CY2023	aagh	Imputed Interest ImputedInterest	5205	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-500	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	15200	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-777340	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4525836	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-777340	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4924936	usd
CY2023	us-gaap	Depreciation Depreciation	10346	usd
CY2022	us-gaap	Depreciation Depreciation	5905	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	15200	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	61596	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	0	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1361133	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	usd
CY2023	aagh	Imputed Interest ImputedInterest	5205	usd
CY2022	aagh	Imputed Interest ImputedInterest	11893	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-919	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	918	usd
CY2023	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	0	usd
CY2022	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-61771	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-2000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	13138	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	0	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	0	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-7709	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	108211	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	13050	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1380314	usd
CY2023	us-gaap	Increase Decrease In Customer Advances IncreaseDecreaseInCustomerAdvances	66331	usd
CY2022	us-gaap	Increase Decrease In Customer Advances IncreaseDecreaseInCustomerAdvances	157000	usd
CY2023	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-7863	usd
CY2022	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	194318	usd
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-88459	usd
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	333415	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-752902	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1479858	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-752902	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1479858	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	44420	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16851	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-44420	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-16851	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	92080	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	97500	usd
CY2023	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	521284	usd
CY2022	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	183932	usd
CY2023	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	324682	usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	639734	usd
CY2023	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-148718	usd
CY2022	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	250109	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	8219	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	789328	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1163056	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-7994	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-333653	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62643	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	396136	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-499	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	160	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54150	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62643	usd
CY2023	us-gaap	Interest Paid InterestPaid	0	usd
CY2022	us-gaap	Interest Paid InterestPaid	0	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2023	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	0	usd
CY2022	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	0	usd
CY2017Q1	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	16155746000	shares
CY2017Q1	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	100	usd
CY2020Q2	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	510000000	shares
CY2021Q3	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	50000	usd
CY2021Q3	us-gaap	Number Of Units In Real Estate Property NumberOfUnitsInRealEstateProperty	53	pure
CY2021Q3	us-gaap	Number Of Real Estate Properties NumberOfRealEstateProperties	19	pure
CY2021Q3	us-gaap	Real Estate Gross At Carrying Value RealEstateGrossAtCarryingValue	7626286.37	usd
CY2021Q3	us-gaap	Payments To Acquire Real Estate PaymentsToAcquireRealEstate	7000000	usd
CY2021Q3	aagh	Real Estate Description Of Terms RealEstateDescriptionOfTerms	The purchase price shall be paid as follows: (i) $1,000,000 on execution of the Agreement, (ii) $2,000,000 within 60 days thereof and (iii) the remainder by April 10, 2022. The Agreement is subject to customary closing conditions, including, satisfactory due diligence.
CY2021Q4	aagh	Class Of Warrant Or Rights Granted ClassOfWarrantOrRightsGranted	500000	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.01
CY2021Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P24M
CY2022Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	500000	shares
CY2021Q4	us-gaap	Investment Owned Balance Shares InvestmentOwnedBalanceShares	20000000	shares
CY2022Q4	aagh	Agreement Description AgreementDescription	The Company A agrees that if the patent is sold or transferred, Men Hwei, Tsai or Men Hwei, Tsai's successor may receive a 25% gain on the transfer or sale of the interest. The Company agrees to give Men Hwei, Tsai an additional 20 million AAGH shares. The Company allows Men Hwei, Tsai to use three years (from November 26, 2022 to November 25, 2025) find investors each with more than US$10 million investment. In case that no investor is found within three years, Men Hwei, Tsai agrees to return the patent to the Company, and both parties will continue to cooperate in accordance with the original contract on May 18, 2021. If Men Hwei, Tsai finds an investor with an investment of at least US$10 million within three years, and the process for Men Hwei, Tsai and its investors to apply for a new drug may last for several years, then Men Hwei, Tsai agrees that the Company will use the patented technology to develop dietary supplement that are helpful to Alzheimer’s disease. The Company will be responsible for marketing the dietary supplement. Men Hwei, Tsai is entitled to commission equaling to 8% of sales price.
CY2022Q4	us-gaap	Other Commitment OtherCommitment	34978.48	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-777340	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-752902	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4525836	usd
CY2023Q2	us-gaap	Cash Cash	54150	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Estimates</b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of the financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include accounting for potential liabilities and the assumptions made in valuing stock instruments issued for services, debt and equity investment. Actual results could differ from those estimates.</p>
CY2023Q2	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	1	pure
CY2023Q2	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	1	pure
CY2023Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	4131	usd
CY2022Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	3194	usd
CY2023Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q2	us-gaap	Other Receivables OtherReceivables	11836	usd
CY2022Q2	us-gaap	Other Receivables OtherReceivables	13836	usd
CY2023Q2	us-gaap	Prepaid Rent PrepaidRent	11836	usd
CY2022Q2	us-gaap	Prepaid Rent PrepaidRent	13836	usd
CY2023Q2	us-gaap	Other Receivables OtherReceivables	11836	usd
CY2022Q2	us-gaap	Other Receivables OtherReceivables	13836	usd
CY2023Q2	aagh	Other Dues To Related Party OtherDuesToRelatedParty	35190	usd
CY2023Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	705216	usd
CY2022Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	183932	usd
CY2022Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.18	pure
CY2023Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	100000	usd
CY2023Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	60000	usd
CY2023Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	80000	usd
CY2022Q3	us-gaap	Interest Paid Net InterestPaidNet	3616	usd
CY2022Q3	aagh	Number Of Loan Agreements NumberOfLoanAgreements	2	pure
CY2023Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	20000	usd
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	1525600	usd
CY2022Q2	us-gaap	Long Term Debt LongTermDebt	1221892	usd
CY2023Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.20	pure
CY2023Q2	us-gaap	Long Term Debt Term LongTermDebtTerm	P5Y
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	402458	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	189754	usd
CY2023	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	1123138	usd
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	402458	usd
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	1525600	usd
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21107018148	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21107018148	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21090218148	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21090218148	shares
CY2022Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1300000	shares
CY2022Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.075
CY2023Q2	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	12200000	shares
CY2023Q2	aagh	Number Of Shareholders NumberOfShareholders	7	pure
CY2023Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.0054
CY2023Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	65880	usd
CY2023Q2	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	3000000	shares
CY2023Q2	aagh	Number Of Unrelated Parties NumberOfUnrelatedParties	3	pure
CY2023Q2	aagh	Number Of Loan Agreements NumberOfLoanAgreements	3	pure
CY2023Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	10000	usd
CY2023Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.20	pure
CY2023Q2	us-gaap	Debt Instrument Term DebtInstrumentTerm	P3Y
CY2023	aagh	Unified Corporate Income Tax Rate UnifiedCorporateIncomeTaxRate	0.25	pure
CY2023	aagh	Corporate Income Tax Rate For Qualified High Technology And Science Enterprises CorporateIncomeTaxRateForQualifiedHighTechnologyAndScienceEnterprises	0.15	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.07	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.07	pure
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6697872	usd
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5920531	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6697872	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5920531	usd
CY2023Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	36556	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	75706	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y7M20D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.05	pure
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	42191	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	36899	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3528	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1764	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	0	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	42191	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	273	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	41918	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	41918	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001098009
CY2022Q4	dei	Entity Public Float EntityPublicFloat	0	usd

Files In Submission

Name	View Source	Status
aagh-20230630_cal.xml	Edgar Link	unprocessable
0001185185-23-001064-index-headers.html	Edgar Link	pending
0001185185-23-001064-index.html	Edgar Link	pending
0001185185-23-001064.txt	Edgar Link	pending
0001185185-23-001064-xbrl.zip	Edgar Link	pending
aagh-20230630.xsd	Edgar Link	pending
amgreat20230630_10k.htm	Edgar Link	pending
amgreat20230630_10kimg001.jpg	Edgar Link	pending
amgreat20230630_10kimg002.jpg	Edgar Link	pending
ex_579772.htm	Edgar Link	pending
ex_579772img001.jpg	Edgar Link	pending
ex_579972.htm	Edgar Link	pending
ex_579973.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
aagh-20230630_def.xml	Edgar Link	unprocessable
aagh-20230630_lab.xml	Edgar Link	unprocessable
aagh-20230630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
amgreat20230630_10k_htm.xml	Edgar Link	completed
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AAGH
America Great Health Stock $aagh

2023 Q3 Form 10-K Financial Statement

#000118518523001064 Filed on October 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AAGH America Great Health Stock $aagh

2023 Q3 Form 10-K Financial Statement

#000118518523001064 Filed on October 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AAGH
America Great Health Stock $aagh